-
公开(公告)号:US07249191B1
公开(公告)日:2007-07-24
申请号:US10251101
申请日:2002-09-20
申请人: Paul Hutchison , Cameron Smith , Vilis Ositis
发明人: Paul Hutchison , Cameron Smith , Vilis Ositis
IPC分类号: G06F15/16
CPC分类号: H04L29/1249 , H04L29/12028 , H04L61/103 , H04L61/256 , H04L67/06 , H04L69/16 , H04L69/163
摘要: A multi-application transparent platform intercepts an incoming application file communicated from a source across a first TCP connection by terminating the first TCP connection on the multi-application transparent platform and supplying the application file to an application program. The application file is received onto the platform in the form of multiple incoming Ethernet frames. The application layer program analyzes the application file and identifies characteristics of the application file, such as virus content, that are not apparent in the individual Ethernet frames that carried the application file over the first TCP connection. The platform resends the application file over a second TCP connection in outgoing frames having the same IP addresses and Ethernet MAC addresses as the incoming frames. The platform can be inserted into a running network without reconfiguring devices on the network.
摘要翻译: 多应用透明平台通过终止多应用透明平台上的第一TCP连接并将应用文件提供给应用程序来拦截通过第一TCP连接从源传送的传入应用文件。 应用文件以多个传入的以太网帧的形式被接收到平台上。 应用层程序分析应用程序文件,并识别通过第一个TCP连接承载应用程序文件的各个以太网帧中不明显的应用程序文件(如病毒内容)的特征。 该平台通过第二个TCP连接在具有与传入帧相同的IP地址和以太网MAC地址的输出帧中重新发送应用程序文件。 该平台可以插入到正在运行的网络中,而无需重新配置网络上的设备。
-
公开(公告)号:US07290050B1
公开(公告)日:2007-10-30
申请号:US10252061
申请日:2002-09-20
申请人: Cameron Smith , Vilis Ositis
发明人: Cameron Smith , Vilis Ositis
IPC分类号: G06F15/173 , G06F9/46
CPC分类号: H04L67/1008 , H04L67/1002 , H04L67/1006 , H04L69/16 , H04L69/165
摘要: A transparent load balancer receives incoming Ethernet frames having incoming source and destination IP and MAC addresses. The load balancer diverts the incoming frames to one of several multi-application platforms. The incoming frames are communicated across a first TCP connection that terminates on a multi-application platform. The first TCP connection is defined by TCP source and destination ports. The transparent load balancer receives outgoing frames from the multi-application platform and outputs the outgoing frames with source and destination IP and MAC addresses that are identical to the incoming source and destination IP and MAC addresses. The outgoing frames are communicated across a second TCP connection, the second TCP connection being defined by the same TCP source port and TCP destination port of the first TCP connection. The transparent load balancer and multi-application platforms can be inserted into a running network without noticeable interruption to devices on the network.
摘要翻译: 透明负载平衡器接收具有传入源和目标IP和MAC地址的入站以太网帧。 负载平衡器将进入的帧转移到几个多应用平台之一。 传入的帧通过在多应用平台上终止的第一TCP连接进行通信。 第一个TCP连接由TCP源端口和目标端口定义。 透明负载平衡器从多应用平台接收输出帧,并输出与源IP和MAC地址相同的源IP和MAC地址的出站帧。 输出帧通过第二TCP连接进行通信,第二TCP连接由第一TCP连接的相同TCP源端口和TCP目标端口定义。 透明负载平衡器和多应用平台可以插入到正在运行的网络中,而不会明显地中断网络上的设备。
-
公开(公告)号:USD980998S1
公开(公告)日:2023-03-14
申请号:US29772180
申请日:2021-02-26
申请人: William Smith , Cameron Smith , Dominic Rainville
设计人: William Smith , Cameron Smith , Dominic Rainville
-
公开(公告)号:US20220221331A1
公开(公告)日:2022-07-14
申请号:US17229586
申请日:2021-04-13
申请人: William Smith , Cameron Smith
发明人: William Smith , Cameron Smith
摘要: Described is a weighing luggage rack having a rack portion with a top section and a bottom section, and a platform portion connected with the top section of the rack portion. In use, the platform portion is stacked on top of the rack portion. The weighing luggage rack further includes a weighing mechanism, and an electronic display configured to display a weight of an object placed thereon. Further embodiments include a weighing luggage rack with only a rack portion and a weighing luggage rack with only a platform portion.
-
公开(公告)号:US20170129880A1
公开(公告)日:2017-05-11
申请号:US15303310
申请日:2015-04-10
申请人: Isao Sakurada , Tomokazu Hirabayashi , Yoshitaka Maeda , Hiroshi Nagasue , Takashi Mizuno , Jiayi Xu , Ting Zhang , Cameron Smith , Dann Parker
发明人: Isao Sakurada , Tomokazu Hirabayashi , Yoshitaka Maeda , Hiroshi Nagasue , Takashi Mizuno , Jiayi Xu , Ting Zhang , Cameron Smith , Dann Parker
IPC分类号: C07D413/14 , A61K45/06 , C07D417/14 , A61K31/428 , C07D471/04 , A61K31/52 , A61K31/506 , A61K31/4439 , C07D519/00 , A61K31/497 , A61K31/501 , A61K31/423 , A61K31/437
CPC分类号: C07D413/14 , A61K31/423 , A61K31/428 , A61K31/437 , A61K31/4439 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/52 , A61K45/06 , C07D413/04 , C07D417/14 , C07D471/04 , C07D498/04 , C07D519/00
摘要: In its many embodiments, the present invention provides a novel class of benzamide compounds represented by Formula (I) or pharmaceutically acceptable salts or solvates thereof, or pharmaceutical compositions comprising one or more said compounds or pharmaceutically acceptable salts or solvates thereof, and methods for using said compounds or pharmaceutically acceptable salts or solvates thereof for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes.
-
公开(公告)号:US20160184316A1
公开(公告)日:2016-06-30
申请号:US14804407
申请日:2015-07-21
申请人: Cameron Smith , Melissa Fleury , Roland Gendron , Ryan Hudson , Adam D. Hughes
发明人: Cameron Smith , Melissa Fleury , Roland Gendron , Ryan Hudson , Adam D. Hughes
IPC分类号: A61K31/5377 , A61K31/4155 , A61K31/454 , A61K31/42 , A61K31/4196 , A61K31/4192 , A61K31/437 , A61K31/422 , A61K31/41 , A61K31/497 , A61K31/421 , A61K31/505 , A61K31/426 , A61K31/50 , A61K31/415
CPC分类号: C07D471/04 , A61K31/41 , A61K31/415 , A61K31/4155 , A61K31/4192 , A61K31/4196 , A61K31/42 , A61K31/421 , A61K31/422 , A61K31/426 , A61K31/437 , A61K31/4439 , A61K31/454 , A61K31/497 , A61K31/50 , A61K31/505 , A61K31/5377 , C07C281/02 , C07D231/14 , C07D231/20 , C07D231/22 , C07D231/40 , C07D237/14 , C07D237/24 , C07D239/28 , C07D239/34 , C07D239/36 , C07D239/52 , C07D239/54 , C07D249/04 , C07D249/10 , C07D249/12 , C07D249/18 , C07D257/04 , C07D261/12 , C07D261/18 , C07D263/32 , C07D263/34 , C07D263/38 , C07D277/34 , C07D277/56 , C07D401/04 , C07D401/06 , C07D403/04 , C07D403/06 , C07D413/04 , Y02P20/55
摘要: In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.
摘要翻译: 一方面,本发明涉及具有下式的化合物:其中R 1 -R 6,a,b和X如说明书中所定义,或其药学上可接受的盐。 这些化合物具有去血清抑制活性。 另一方面,本发明涉及包含这些化合物的药物组合物; 使用这些化合物的方法; 以及制备这些化合物的方法和中间体。
-
公开(公告)号:US08563512B2
公开(公告)日:2013-10-22
申请号:US13325453
申请日:2011-12-14
申请人: Cameron Smith , Melissa Fleury , Roland Gendron , Ryan Hudson , Adam D. Hughes
发明人: Cameron Smith , Melissa Fleury , Roland Gendron , Ryan Hudson , Adam D. Hughes
IPC分类号: C07D231/14 , C07D231/20 , C07D231/22 , C07D231/40 , C07D237/24 , C07D239/36 , C07D239/54 , C07D249/04
CPC分类号: C07D471/04 , A61K31/41 , A61K31/415 , A61K31/4155 , A61K31/4192 , A61K31/4196 , A61K31/42 , A61K31/421 , A61K31/422 , A61K31/426 , A61K31/437 , A61K31/4439 , A61K31/454 , A61K31/497 , A61K31/50 , A61K31/505 , A61K31/5377 , C07C281/02 , C07D231/14 , C07D231/20 , C07D231/22 , C07D231/40 , C07D237/14 , C07D237/24 , C07D239/28 , C07D239/34 , C07D239/36 , C07D239/52 , C07D239/54 , C07D249/04 , C07D249/10 , C07D249/12 , C07D249/18 , C07D257/04 , C07D261/12 , C07D261/18 , C07D263/32 , C07D263/34 , C07D263/38 , C07D277/34 , C07D277/56 , C07D401/04 , C07D401/06 , C07D403/04 , C07D403/06 , C07D413/04 , Y02P20/55
摘要: In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.
-
公开(公告)号:US08449890B2
公开(公告)日:2013-05-28
申请号:US13398027
申请日:2012-02-16
申请人: Melissa Fleury , Roland Gendron , Adam D. Hughes , Cameron Smith
发明人: Melissa Fleury , Roland Gendron , Adam D. Hughes , Cameron Smith
IPC分类号: A61K9/00 , A61K31/33 , A61K33/36 , A61P35/00 , C07C229/02 , C07C271/10
CPC分类号: C07D471/04 , A61K31/415 , A61K31/4192 , A61K31/4196 , A61K31/42 , A61K31/437 , A61K31/505 , A61K45/06 , C07C243/28 , C07C271/22 , C07C2601/02 , C07D231/14 , C07D231/20 , C07D239/34 , C07D239/36 , C07D249/04 , C07D249/10 , C07D249/18 , C07D257/04 , C07D261/12 , C07D261/18 , C07D403/04 , C07D487/04
摘要: In one aspect, the invention relates to compounds having the formula: where R1, R2a, R2b, R3-R6, a, b, Z, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.
摘要翻译: 一方面,本发明涉及具有下式的化合物:其中R1,R2a,R2b,R3-R6,a,b,Z和X如说明书中所定义,或其药学上可接受的盐。 这些化合物具有去血清抑制活性。 另一方面,本发明涉及包含这些化合物的药物组合物; 使用这些化合物的方法; 以及制备这些化合物的方法和中间体。
-
公开(公告)号:USD670391S1
公开(公告)日:2012-11-06
申请号:US29381389
申请日:2010-12-17
申请人: James P. Goodman , Cameron Smith , Bryan Cabatic , Adam Smith , Adam Weisgerber
设计人: James P. Goodman , Cameron Smith , Bryan Cabatic , Adam Smith , Adam Weisgerber
-
公开(公告)号:US20110218177A1
公开(公告)日:2011-09-08
申请号:US13121972
申请日:2009-09-21
申请人: Sander G. Mills , Amjad Ali , Cameron Smith
发明人: Sander G. Mills , Amjad Ali , Cameron Smith
IPC分类号: A61K31/661 , C07C219/22 , A61K31/265 , C07C329/06 , C07F9/06 , C07F9/38 , A61K31/662 , A61P3/00 , A61P3/06
CPC分类号: A61K31/42 , C07C219/22 , C07C219/28 , C07C229/36 , C07C329/06 , C07C2601/14 , C07F9/091 , C07F9/093 , C07F9/094
摘要: The compounds of Formula I are pro-drugs of CETP inhibitors having a central oxazolidinone ring. The compounds cyclize by the elimination of HX to form an oxazolidinone ring after administration to a patient.
摘要翻译: 式I的化合物是具有中心恶唑烷酮环的CETP抑制剂的前药。 通过消除HX,在给予患者后,化合物环化形成恶唑烷酮环。
-
-
-
-
-
-
-
-
-